Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial

Sherf-Dagan, Shiri; Zelber‐Sagi, Shira; Zilberman-Schapira, Gili; Webb, Muriel; Buch, Assaf; Keidar, Andrei; Raziel, Asnat; Sakran, Nasser; Goitein, David; Goldenberg, Neil A.; Mahdi, Jemal Ali; Pevsner‐Fischer, Meirav; Zmora, Niv; Dori-Bachash, Mally; Segal, Eran; Elinav, Eran; Shibolet, Oren

doi:10.1038/ijo.2017.210

Cited by 51 publications

(40 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We identified 1934 records, from which we selected 986 individual abstracts and 161 potentially relevant articles for full review (figure 1). We identified 105 articles19 25–128 reporting data from 99 different research studies including 111 different randomised comparisons of probiotics versus control (further called randomised clinical trials [RCTs], see online supplementary table 1-2) with the following outcomes: BW (number of RCTs: k=58, n=3422 individuals, median=77.4 kg), BMI (k=68, n=4015, 28.2 kg/m²), WC (k=26, n=1583, 98.8 cm); BFM (k=27, n=1562, 27.8 kg), SAT and VAT (k=5, n=543, 192.4 cm² and 114.7 cm², respectively), FG (k=83, n=5188, 6.1 mmol), HbA 1c (k=28, n=1796, 6.3%), INS (k=63, n=3854, 11.0 mU/L), HOMA-IR (k=52, n=3513, 3.2), CRP (k=41, n=2376, 3.6 mg/L), TG (k=74, n=4461, 145.4 mg/dL), ALAT (k=26, n=1466, 38.6 IU/L), ASAT (k=23, n=1340, 36.1 IU/L) and GGT (k=14, n=816, 41.5 IU/L). The median duration of the follow-up was 8 weeks (range: 2–28 weeks), probiotics dose ranged from 10 7 to 10 12 CFU daily, and 43 trials were conducted in one country (Iran).…”

Section: Resultsmentioning

confidence: 99%

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children <3 years.ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body mass index (k=32, d=−0.55 kg/m², 95% CI −0.86 to −0.23, I²=91.9%), waist circumference (k=13, d=−1.31 cm, 95% CI −1.79 to −0.83, I²=14.5%), body fat mass (k=11, d=−0.96 kg, 95% CI −1.21 to −0.71, I²=0.0%) and visceral adipose tissue mass (k=5, d=−6.30 cm², 95% CI −9.05 to −3.56, I²=0.0%). In type 2 diabetics, probiotics reduced fasting glucose (k=19, d=−0.66 mmol/L, 95% CI −1.00 to −0.31, I²=27.7%), glycated haemoglobin (k=13, d=−0.28 pp, 95% CI −0.46 to −0.11, I²=54.1%), insulin (k=13, d=−1.66 mU/L, 95% CI −2.70 to −0.61, I²=37.8%) and homeostatic model of insulin resistance (k=10, d=−1.05 pp, 95% CI −1.48 to −0.61, I²=18.2%). In subjects with fatty liver diseases, probiotics reduced alanine (k=12, d=−10.2 U/L, 95% CI −14.3 to −6.0, I²=93.50%) and aspartate aminotransferases (k=10, d=−9.9 U/L, 95% CI −14.1 to -5.8, I²=96.1%). These improvements were mostly observed with bifidobacteria (Bifidobacterium breve, B. longum), Streptococcus salivarius subsp. thermophilus and lactobacilli (Lactobacillus acidophilus, L. casei, L. delbrueckii) containing mixtures and influenced by trials conducted in one country.ConclusionsThe intake of probiotics resulted in minor but consistent improvements in several metabolic risk factors in subjects with metabolic diseases.Trial registration numberCRD42016033273.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Human studies on the efficacy of conventional probiotics after BS is limited, although the usage of probiotics is common postoperatively [192]. To date, the effects of probiotics following weight loss surgery have been analyzed by 4 studies, out of which, 3 were conducted on patients with obesity who underwent RYGB and 1 was performed among patients submitted to VSG [181,193,194].…”

Section: Probiotics and Gm: Implications For Bariatric Patientsmentioning

confidence: 99%

“…To date, the effects of probiotics following weight loss surgery have been analyzed by 4 studies, out of which, 3 were conducted on patients with obesity who underwent RYGB and 1 was performed among patients submitted to VSG [181,193,194]. The latter did not report any improvements in hepatic, inflammatory, or other clinical endpoints associated with probiotic therapy at 6 months, respectively 1 year following surgery, suggesting that VSG in itself results in major metabolic changes, leaving little or no room for an extra effect [192]. On the other hand, Chen et al observed alleviation of gastrointestinal symptoms and improvement in quality of life in 60 RYGB patients two weeks after the initiation of probiotics and digestive enzymes therapy [193].…”

Section: Probiotics and Gm: Implications For Bariatric Patientsmentioning

confidence: 99%

Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status

et al. 2020

View full text Add to dashboard Cite

Obesity is associated with reduced gut microbial diversity and a high rate of micronutrient deficiency. Bariatric surgery, the therapy of choice for severe obesity, produces sustained weight loss and improvements in obesity-related comorbidities. Also, it significantly alters the gut microbiota (GM) composition and function, which might have an important impact on the micronutrient status as GM is able to synthesize certain vitamins, such as riboflavin, folate, B12, or vitamin K2. However, recent data have reported that GM is not fully restored after bariatric surgery; therefore, manipulation of GM through probiotics represents a promising therapeutic approach in bariatric patients. In this review, we discuss the latest evidence concerning the relationship between obesity, GM and micronutrients, the impact of bariatric surgery on GM in relation with micronutrients equilibrium, and the importance of the probiotics’ supplementation in obese patients submitted to surgical treatment.

show abstract

“…One study found that RYGB patients taking 2.4 billion Lactobacillus daily for 6 months after surgery experienced lower bacterial overgrowth, greater short term weight loss, and improved vitamin B12 status over patients not taking the probiotic [94]. However, two other studies with different design found no added benefit of probiotic supplementation over placebo in measured outcomes [95,96]. Similarly to CR interventions, more studies testing varying doses and strains of bacteria are needed to clarify whether there is an added benefit of probiotic supplementation after BS.…”

Section: Do Prebiotics and Probiotics Aid In Weight Loss Interventions?mentioning

confidence: 99%

Gut microbiota and obesity: Concepts relevant to clinical care

Dao¹,

Clément²

2018

European Journal of Internal Medicine

104

View full text Add to dashboard Cite

The composition and function of gut microbiota play a role in obesity and metabolic disease, yet the mechanisms have not been fully described. As new discoveries and advances in the field have occurred, the relevance of gut microbiota in clinical care has become more substantial. There is promising potential for manipulation of the gut microbiota as treatment of obesity and associated health complications, both as a standalone therapy and as part of interventions such as weight loss. In this review we have compiled knowledge and concepts that are important in the consideration of gut microbiota for clinical care.

show abstract

Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial

Abstract: Probiotics administration does not improve hepatic, inflammatory and clinical outcomes 6- and 12 months post-LSG.

Cited by 51 publications

References 38 publications

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status

Gut microbiota and obesity: Concepts relevant to clinical care

Contact Info

Product

Resources

About